ROCKVILLE, Md., Jan. 14, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients. This open-label, multi-site study, will enroll up to eight patients with thoracic spinal cord injuries (T2-T12), who have an American Spinal Injury Association (AIS) A level of impairment, between one and two years after injury. AIS A impairment refers to a patient with no motor or sensory function in the relevant segments at and below the injury, and is considered to be complete paralysis.
PR Newswire (http://s.tt/1ypnb)
- Two Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board
- Get registered for Working 2 Walk 2017 today!
- Airline lobby wins another big delay on reporting data for wheelchair damages and losses *January 2019*
- An injectable hydrogel enhances tissue repair after spinal cord injury by promoting extracellular matrix remodeling
- 17th International Symposium on Neural Regeneration
- Combinatory repair strategy to promote axon regeneration and functional recovery after chronic spinal cord injury
- Gait Rehabilitation with a Neurologically Controlled Exoskeleton
- Nanoparticles limit damage in spinal cord injury
- It’s Not a Rat’s Race for Human Stem Cells Grafted to Repair Spinal Cord Injuries
- It’s On! U2FP Working 2 Walk 2017 and SCI Curecast Episode 11
- InVivo Therapeutics restructures and suspends chronic SCI stem cell and gene therapy research programs
- Pretreatment May Unlock the Regenerative Potential of Neural Stem Cells in Chronic Spinal Cord Injury
- Regulateable Chondroitinase ABC gene therapy as a treatment for spinal cord injury
- Miracle chemical ‘cocktail’ could cure spinal cord damage
- Combined expression of pro-regenerative transcription factors and transplanted stem cells to promote corticospinal tract regeneration.
Follow on TwitterMy Tweets